NuVasive, Inc.

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUVA is priced at $39.75, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NUVA is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BSX-PA's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ISRG has a market cap of 149.1B. Regarding current trading prices, NUVA is priced at $39.75, while ISRG trades at $421.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ISRG's P/E ratio is 51.29. In terms of profitability, NUVA's ROE is +0.05%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, NUVA is more volatile compared to ISRG. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ISRG's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABT has a market cap of 147.1B. Regarding current trading prices, NUVA is priced at $39.75, while ABT trades at $84.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ABT's P/E ratio is 23.66. In terms of profitability, NUVA's ROE is +0.05%, compared to ABT's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ABT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SYK has a market cap of 117.6B. Regarding current trading prices, NUVA is priced at $39.75, while SYK trades at $306.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SYK's P/E ratio is 35.50. In terms of profitability, NUVA's ROE is +0.05%, compared to SYK's ROE of +0.15%. Regarding short-term risk, NUVA is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SYK's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, MDT has a market cap of 97.8B. Regarding current trading prices, NUVA is priced at $39.75, while MDT trades at $76.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas MDT's P/E ratio is 21.28. In terms of profitability, NUVA's ROE is +0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check MDT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX has a market cap of 78.3B. Regarding current trading prices, NUVA is priced at $39.75, while BSX trades at $52.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BSX's P/E ratio is 22.05. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NUVA is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BSX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BRKRP has a market cap of 50.4B. Regarding current trading prices, NUVA is priced at $39.75, while BRKRP trades at $332.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BRKRP's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BRKRP's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, EW has a market cap of 46.9B. Regarding current trading prices, NUVA is priced at $39.75, while EW trades at $81.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas EW's P/E ratio is 43.99. In terms of profitability, NUVA's ROE is +0.05%, compared to EW's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check EW's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, RMD has a market cap of 29.3B. Regarding current trading prices, NUVA is priced at $39.75, while RMD trades at $201.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas RMD's P/E ratio is 19.49. In terms of profitability, NUVA's ROE is +0.05%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NUVA is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check RMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PHG has a market cap of 24B. Regarding current trading prices, NUVA is priced at $39.75, while PHG trades at $25.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PHG's P/E ratio is 21.58. In terms of profitability, NUVA's ROE is +0.05%, compared to PHG's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check PHG's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, DXCM has a market cap of 23.8B. Regarding current trading prices, NUVA is priced at $39.75, while DXCM trades at $61.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas DXCM's P/E ratio is 26.45. In terms of profitability, NUVA's ROE is +0.05%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, NUVA is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check DXCM's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, STE has a market cap of 20.8B. Regarding current trading prices, NUVA is priced at $39.75, while STE trades at $212.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas STE's P/E ratio is 26.72. In terms of profitability, NUVA's ROE is +0.05%, compared to STE's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check STE's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUVA is priced at $39.75, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUVA's ROE is +0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ABMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZBH has a market cap of 16.2B. Regarding current trading prices, NUVA is priced at $39.75, while ZBH trades at $83.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ZBH's P/E ratio is 21.68. In terms of profitability, NUVA's ROE is +0.05%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NUVA is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ZBH's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, NUVA is priced at $39.75, while PEN trades at $322.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PEN's P/E ratio is 74.46. In terms of profitability, NUVA's ROE is +0.05%, compared to PEN's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check PEN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, NUVA is priced at $39.75, while SNN trades at $29.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SNN's P/E ratio is 20.66. In terms of profitability, NUVA's ROE is +0.05%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SNN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUVA is priced at $39.75, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUVA's ROE is +0.05%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NUVA is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SWAV's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ALGN has a market cap of 11.3B. Regarding current trading prices, NUVA is priced at $39.75, while ALGN trades at $157.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ALGN's P/E ratio is 26.43. In terms of profitability, NUVA's ROE is +0.05%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ALGN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, GMED has a market cap of 10.3B. Regarding current trading prices, NUVA is priced at $39.75, while GMED trades at $76.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas GMED's P/E ratio is 17.90. In terms of profitability, NUVA's ROE is +0.05%, compared to GMED's ROE of +0.13%. Regarding short-term risk, NUVA is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check GMED's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PODD has a market cap of 10.2B. Regarding current trading prices, NUVA is priced at $39.75, while PODD trades at $147.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PODD's P/E ratio is 34.45. In terms of profitability, NUVA's ROE is +0.05%, compared to PODD's ROE of +0.21%. Regarding short-term risk, NUVA is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PODD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, MASI has a market cap of 9.3B. Regarding current trading prices, NUVA is priced at $39.75, while MASI trades at $178.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas MASI's P/E ratio is 44.29. In terms of profitability, NUVA's ROE is +0.05%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check MASI's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, GKOS has a market cap of 8.5B. Regarding current trading prices, NUVA is priced at $39.75, while GKOS trades at $144.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas GKOS's P/E ratio is -43.77. In terms of profitability, NUVA's ROE is +0.05%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, NUVA is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check GKOS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO has a market cap of 6.7B. Regarding current trading prices, NUVA is priced at $39.75, while BIO trades at $247.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BIO's P/E ratio is 41.20. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO's ROE of +0.02%. Regarding short-term risk, NUVA is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BIO's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, NUVA is priced at $39.75, while BIO-B trades at $260.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BIO-B's P/E ratio is 41.12. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, NUVA is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BIO-B's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BRKR has a market cap of 6.5B. Regarding current trading prices, NUVA is priced at $39.75, while BRKR trades at $42.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BRKR's P/E ratio is -178.67. In terms of profitability, NUVA's ROE is +0.05%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check BRKR's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUVA is priced at $39.75, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUVA's ROE is +0.05%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NUVA is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check NARI's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, LIVN has a market cap of 3.8B. Regarding current trading prices, NUVA is priced at $39.75, while LIVN trades at $70.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas LIVN's P/E ratio is 35.71. In terms of profitability, NUVA's ROE is +0.05%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check LIVN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRTC has a market cap of 3.7B. Regarding current trading prices, NUVA is priced at $39.75, while IRTC trades at $114.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas IRTC's P/E ratio is -134.12. In terms of profitability, NUVA's ROE is +0.05%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, NUVA is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check IRTC's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUVA is priced at $39.75, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUVA's ROE is +0.05%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AXNX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, NUVA is priced at $39.75, while ITGR trades at $88.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ITGR's P/E ratio is 21.91. In terms of profitability, NUVA's ROE is +0.05%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, NUVA is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ITGR's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMDX has a market cap of 2.2B. Regarding current trading prices, NUVA is priced at $39.75, while TMDX trades at $63.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas TMDX's P/E ratio is 14.46. In terms of profitability, NUVA's ROE is +0.05%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, NUVA is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TMDX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, NUVA is priced at $39.75, while AXGN trades at $40.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas AXGN's P/E ratio is -64.05. In terms of profitability, NUVA's ROE is +0.05%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, NUVA is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AXGN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, NUVA is priced at $39.75, while ESTA trades at $65.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ESTA's P/E ratio is -44.73. In terms of profitability, NUVA's ROE is +0.05%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, NUVA is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ESTA's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, NUVA is priced at $39.75, while UFPT trades at $213.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas UFPT's P/E ratio is 24.37. In terms of profitability, NUVA's ROE is +0.05%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NUVA is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check UFPT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, NUVA is priced at $39.75, while PRCT trades at $26.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PRCT's P/E ratio is -14.27. In terms of profitability, NUVA's ROE is +0.05%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, NUVA is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PRCT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, NUVA is priced at $39.75, while AHCO trades at $10.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas AHCO's P/E ratio is -18.07. In terms of profitability, NUVA's ROE is +0.05%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, NUVA is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AHCO's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ENOV has a market cap of 1.4B. Regarding current trading prices, NUVA is priced at $39.75, while ENOV trades at $24.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ENOV's P/E ratio is -1.22. In terms of profitability, NUVA's ROE is +0.05%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, NUVA is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ENOV's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUVA's ROE is +0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check HSKA's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, NUVA is priced at $39.75, while ATEC trades at $7.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ATEC's P/E ratio is -9.23. In terms of profitability, NUVA's ROE is +0.05%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, NUVA is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ATEC's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NUVA is priced at $39.75, while AVNS trades at $24.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas AVNS's P/E ratio is -15.46. In terms of profitability, NUVA's ROE is +0.05%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NUVA is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check AVNS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, NUVA is priced at $39.75, while INSP trades at $40.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas INSP's P/E ratio is 9.10. In terms of profitability, NUVA's ROE is +0.05%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NUVA is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check INSP's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUVA's ROE is +0.05%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NUVA is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SILK's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while IRMD trades at $86.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas IRMD's P/E ratio is 47.23. In terms of profitability, NUVA's ROE is +0.05%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, NUVA is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check IRMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while AORT trades at $22.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas AORT's P/E ratio is 91.04. In terms of profitability, NUVA's ROE is +0.05%, compared to AORT's ROE of +0.03%. Regarding short-term risk, NUVA is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check AORT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUVA's ROE is +0.05%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NUVA is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check FNA's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while IART trades at $14.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas IART's P/E ratio is -2.18. In terms of profitability, NUVA's ROE is +0.05%, compared to IART's ROE of -0.48%. Regarding short-term risk, NUVA is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check IART's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75, while CNMD trades at $35.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CNMD's P/E ratio is 20.05. In terms of profitability, NUVA's ROE is +0.05%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, NUVA is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CNMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BFLY has a market cap of 999.5M. Regarding current trading prices, NUVA is priced at $39.75, while BFLY trades at $3.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BFLY's P/E ratio is -12.73. In terms of profitability, NUVA's ROE is +0.05%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, NUVA is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BFLY's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, INMD has a market cap of 880.7M. Regarding current trading prices, NUVA is priced at $39.75, while INMD trades at $13.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas INMD's P/E ratio is 10.30. In terms of profitability, NUVA's ROE is +0.05%, compared to INMD's ROE of +0.13%. Regarding short-term risk, NUVA is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check INMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, TNDM has a market cap of 878.5M. Regarding current trading prices, NUVA is priced at $39.75, while TNDM trades at $12.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas TNDM's P/E ratio is -9.36. In terms of profitability, NUVA's ROE is +0.05%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, NUVA is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TNDM's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUVA is priced at $39.75, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUVA's ROE is +0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUVA is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check CSII's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SSII has a market cap of 772.5M. Regarding current trading prices, NUVA is priced at $39.75, while SSII trades at $3.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SSII's P/E ratio is -77.20. In terms of profitability, NUVA's ROE is +0.05%, compared to SSII's ROE of -0.23%. Regarding short-term risk, NUVA is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SSII's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, NUVA is priced at $39.75, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CRY's P/E ratio is 425.71. In terms of profitability, NUVA's ROE is +0.05%, compared to CRY's ROE of +0.03%. Regarding short-term risk, NUVA is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CRY's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BVS has a market cap of 716.8M. Regarding current trading prices, NUVA is priced at $39.75, while BVS trades at $10.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BVS's P/E ratio is 25.80. In terms of profitability, NUVA's ROE is +0.05%, compared to BVS's ROE of +0.16%. Regarding short-term risk, NUVA is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BVS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, LMRI has a market cap of 675.7M. Regarding current trading prices, NUVA is priced at $39.75, while LMRI trades at $7.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas LMRI's P/E ratio is -10.65. In terms of profitability, NUVA's ROE is +0.05%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, NUVA is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check LMRI's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SIBN has a market cap of 628M. Regarding current trading prices, NUVA is priced at $39.75, while SIBN trades at $14.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SIBN's P/E ratio is -36.31. In terms of profitability, NUVA's ROE is +0.05%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, NUVA is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SIBN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CBLL has a market cap of 618.5M. Regarding current trading prices, NUVA is priced at $39.75, while CBLL trades at $16.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CBLL's P/E ratio is -10.06. In terms of profitability, NUVA's ROE is +0.05%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, NUVA is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check CBLL's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NUVA is priced at $39.75, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NUVA's ROE is +0.05%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, NUVA is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SRDX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BWAY has a market cap of 589.5M. Regarding current trading prices, NUVA is priced at $39.75, while BWAY trades at $15.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BWAY's P/E ratio is 83.50. In terms of profitability, NUVA's ROE is +0.05%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, NUVA is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BWAY's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUVA is priced at $39.75, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUVA's ROE is +0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUVA is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check APEN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NUVA is priced at $39.75, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NUVA's ROE is +0.05%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check ZIMV's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, NPCE has a market cap of 523.7M. Regarding current trading prices, NUVA is priced at $39.75, while NPCE trades at $15.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas NPCE's P/E ratio is -23.63. In terms of profitability, NUVA's ROE is +0.05%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, NUVA is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check NPCE's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, TCMD has a market cap of 512.9M. Regarding current trading prices, NUVA is priced at $39.75, while TCMD trades at $22.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas TCMD's P/E ratio is 26.14. In terms of profitability, NUVA's ROE is +0.05%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check TCMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, OFIX has a market cap of 485.5M. Regarding current trading prices, NUVA is priced at $39.75, while OFIX trades at $12.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas OFIX's P/E ratio is -8.01. In terms of profitability, NUVA's ROE is +0.05%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, NUVA is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check OFIX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CERS has a market cap of 468.9M. Regarding current trading prices, NUVA is priced at $39.75, while CERS trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CERS's P/E ratio is -46.80. In terms of profitability, NUVA's ROE is +0.05%, compared to CERS's ROE of -0.15%. Regarding short-term risk, NUVA is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CERS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, KIDS has a market cap of 455.1M. Regarding current trading prices, NUVA is priced at $39.75, while KIDS trades at $17.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas KIDS's P/E ratio is -10.55. In terms of profitability, NUVA's ROE is +0.05%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, NUVA is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check KIDS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CTKB has a market cap of 439.7M. Regarding current trading prices, NUVA is priced at $39.75, while CTKB trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CTKB's P/E ratio is -6.42. In terms of profitability, NUVA's ROE is +0.05%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, NUVA is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CTKB's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, VREX has a market cap of 406.7M. Regarding current trading prices, NUVA is priced at $39.75, while VREX trades at $9.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas VREX's P/E ratio is -4.83. In terms of profitability, NUVA's ROE is +0.05%, compared to VREX's ROE of -0.18%. Regarding short-term risk, NUVA is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check VREX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, LAB has a market cap of 384.4M. Regarding current trading prices, NUVA is priced at $39.75, while LAB trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas LAB's P/E ratio is -7.58. In terms of profitability, NUVA's ROE is +0.05%, compared to LAB's ROE of -0.21%. Regarding short-term risk, NUVA is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check LAB's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, DCTH has a market cap of 382.2M. Regarding current trading prices, NUVA is priced at $39.75, while DCTH trades at $11.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas DCTH's P/E ratio is 1107.00. In terms of profitability, NUVA's ROE is +0.05%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, NUVA is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check DCTH's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, VMD has a market cap of 358.4M. Regarding current trading prices, NUVA is priced at $39.75, while VMD trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas VMD's P/E ratio is 25.27. In terms of profitability, NUVA's ROE is +0.05%, compared to VMD's ROE of +0.11%. Regarding short-term risk, NUVA is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check VMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CLPT has a market cap of 349.1M. Regarding current trading prices, NUVA is priced at $39.75, while CLPT trades at $11.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CLPT's P/E ratio is -11.64. In terms of profitability, NUVA's ROE is +0.05%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, NUVA is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CLPT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PACB has a market cap of 347.9M. Regarding current trading prices, NUVA is priced at $39.75, while PACB trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PACB's P/E ratio is -2.73. In terms of profitability, NUVA's ROE is +0.05%, compared to PACB's ROE of -4.88%. Regarding short-term risk, NUVA is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PACB's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NUVA is priced at $39.75, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NUVA's ROE is +0.05%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, NUVA is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check SMLR's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CATX has a market cap of 297.8M. Regarding current trading prices, NUVA is priced at $39.75, while CATX trades at $3.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CATX's P/E ratio is -2.73. In terms of profitability, NUVA's ROE is +0.05%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NUVA is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CATX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ELMD has a market cap of 295M. Regarding current trading prices, NUVA is priced at $39.75, while ELMD trades at $35.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ELMD's P/E ratio is 30.45. In terms of profitability, NUVA's ROE is +0.05%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, NUVA is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ELMD's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SGHT has a market cap of 271M. Regarding current trading prices, NUVA is priced at $39.75, while SGHT trades at $4.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SGHT's P/E ratio is -7.11. In terms of profitability, NUVA's ROE is +0.05%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, NUVA is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SGHT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVR has a market cap of 266.3M. Regarding current trading prices, NUVA is priced at $39.75, while AVR trades at $7.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas AVR's P/E ratio is -2.94. In terms of profitability, NUVA's ROE is +0.05%, compared to AVR's ROE of -1.24%. Regarding short-term risk, NUVA is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check AVR's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, MASS has a market cap of 260.9M. Regarding current trading prices, NUVA is priced at $39.75, while MASS trades at $6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas MASS's P/E ratio is -7.11. In terms of profitability, NUVA's ROE is +0.05%, compared to MASS's ROE of -0.26%. Regarding short-term risk, NUVA is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check MASS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PMI has a market cap of 244.5M. Regarding current trading prices, NUVA is priced at $39.75, while PMI trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PMI's P/E ratio is -0.21. In terms of profitability, NUVA's ROE is +0.05%, compared to PMI's ROE of +2.17%. Regarding short-term risk, NUVA is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PMI's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NUVA is priced at $39.75, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas MGRM's P/E ratio is -11.11. In terms of profitability, NUVA's ROE is +0.05%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, NUVA is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check MGRM's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SENS has a market cap of 241.2M. Regarding current trading prices, NUVA is priced at $39.75, while SENS trades at $5.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SENS's P/E ratio is -2.93. In terms of profitability, NUVA's ROE is +0.05%, compared to SENS's ROE of -1.30%. Regarding short-term risk, NUVA is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SENS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, RXST has a market cap of 235.1M. Regarding current trading prices, NUVA is priced at $39.75, while RXST trades at $5.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas RXST's P/E ratio is -5.03. In terms of profitability, NUVA's ROE is +0.05%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NUVA is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check RXST's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUVA is priced at $39.75, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUVA's ROE is +0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUVA is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check NVRO's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, PROF has a market cap of 210.9M. Regarding current trading prices, NUVA is priced at $39.75, while PROF trades at $6.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas PROF's P/E ratio is -5.62. In terms of profitability, NUVA's ROE is +0.05%, compared to PROF's ROE of -0.71%. Regarding short-term risk, NUVA is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check PROF's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, NUVA is priced at $39.75, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas EYES's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to EYES's ROE of -2.64%. Regarding short-term risk, NUVA is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check EYES's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, ANIK has a market cap of 198.4M. Regarding current trading prices, NUVA is priced at $39.75, while ANIK trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas ANIK's P/E ratio is -18.87. In terms of profitability, NUVA's ROE is +0.05%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, NUVA is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check ANIK's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NUVA is priced at $39.75, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NUVA's ROE is +0.05%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, NUVA is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check BSGM's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NUVA is priced at $39.75, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NUVA's ROE is +0.05%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NUVA is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check MDGS's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, INGN has a market cap of 172.7M. Regarding current trading prices, NUVA is priced at $39.75, while INGN trades at $6.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas INGN's P/E ratio is -7.01. In terms of profitability, NUVA's ROE is +0.05%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NUVA is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check INGN's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMCI has a market cap of 172.6M. Regarding current trading prices, NUVA is priced at $39.75, while TMCI trades at $2.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas TMCI's P/E ratio is -2.77. In terms of profitability, NUVA's ROE is +0.05%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, NUVA is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check TMCI's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, APYX has a market cap of 169.6M. Regarding current trading prices, NUVA is priced at $39.75, while APYX trades at $4.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas APYX's P/E ratio is -18.41. In terms of profitability, NUVA's ROE is +0.05%, compared to APYX's ROE of -0.91%. Regarding short-term risk, NUVA is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check APYX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NUVA is priced at $39.75, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NUVA's ROE is +0.05%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NUVA is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for NUVA.Check QIPT's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, CVRX has a market cap of 158.3M. Regarding current trading prices, NUVA is priced at $39.75, while CVRX trades at $5.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas CVRX's P/E ratio is -2.98. In terms of profitability, NUVA's ROE is +0.05%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, NUVA is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check CVRX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, EDAP has a market cap of 156.3M. Regarding current trading prices, NUVA is priced at $39.75, while EDAP trades at $4.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas EDAP's P/E ratio is -5.09. In terms of profitability, NUVA's ROE is +0.05%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, NUVA is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check EDAP's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, QTI has a market cap of 147.9M. Regarding current trading prices, NUVA is priced at $39.75, while QTI trades at $5.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas QTI's P/E ratio is -2.71. In terms of profitability, NUVA's ROE is +0.05%, compared to QTI's ROE of -63.30%. Regarding short-term risk, NUVA is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check QTI's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNWV has a market cap of 144.9M. Regarding current trading prices, NUVA is priced at $39.75, while SNWV trades at $16.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas SNWV's P/E ratio is 17.55. In terms of profitability, NUVA's ROE is +0.05%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, NUVA is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check SNWV's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, QTRX has a market cap of 129.5M. Regarding current trading prices, NUVA is priced at $39.75, while QTRX trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas QTRX's P/E ratio is -1.17. In terms of profitability, NUVA's ROE is +0.05%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, NUVA is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check QTRX's competition here

NUVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NUVA stands at 2.1B. In comparison, HYPR has a market cap of 129.4M. Regarding current trading prices, NUVA is priced at $39.75, while HYPR trades at $1.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NUVA currently has a P/E ratio of 75.00, whereas HYPR's P/E ratio is -3.87. In terms of profitability, NUVA's ROE is +0.05%, compared to HYPR's ROE of -1.01%. Regarding short-term risk, NUVA is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for NUVA.Check HYPR's competition here